SPRO · Spero Therapeutics, Inc. · Metrics
Market Cap
$70.46M
Shares
58.23M
SPRO metrics
61 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$1.19
Market cap
$70.46M
Price action
20 metricsPrice change (1W)
+0.8%
Price change (30D)
-1.6%
Price change (3M)
-57.1%
Price change (6M)
-47.4%
Price change (YTD)
-48.1%
Price change (1Y)
-43.5%
Trailing year
Price change (5Y)
-93.2%
52-week high
$2.98
52-week low
$1.15
Change from 52-week high
-59.4%
Change from 52-week low
+5.2%
Annualized volatility
60.8%
Annualized volatility (3M)
85.7%
Beta
1.5
RSI (14D)
38.0
Price vs SMA 50
-17.7%
Price vs SMA 200
-45.4%
Avg volume (3M)
1.48M
Relative volume
0.3
Average dollar volume
$2.56M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
58.23M
Valuation
12 metricsP / E (TTM)
8.6
Trailing earnings · reciprocal yield 11.6%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 66.7%
P / book
1.6
reciprocal yield 62.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
3.6
reciprocal yield 27.8%
Earnings yield
10.5%
Historical valuation
8 metricsP / E historical average (3Y)
8.6×
reciprocal yield 11.6%
P / E historical average (5Y)
8.6×
reciprocal yield 11.6%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-12
Profitability
9 metricsGross margin
—
Operating margin
12.8%
Trailing 12 months
Net margin
15.7%
Gross profit (TTM)
—
Operating profit (TTM)
$6.03M
Net income (TTM)
$7.38M
Trailing 12 months
Diluted EPS (TTM)
$0.14
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$47.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
+7.7%
Revenue CAGR (5Y)
+48.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
16.7%
Return on assets
14.0%
Debt / equity
—
Current ratio
6.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
6.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$50.77M
Total assets
$52.77M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$19.58M
Capital expenditures (TTM)
$12,000
R&D (TTM)
$20.53M
SG&A (TTM)
—
Stock compensation (TTM)
$3.99M
R&D / revenue
43.7%
Stock compensation / revenue
8.5%
Ownership (13F)
3 metrics13F filers
62
13F filer change QoQ
+12
Institutional ownership
37.2%
Short interest
3 metricsShort interest
2.5%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
47 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—